Gastroenterology

Gastroenterology

Volume 143, Issue 5, November 2012, Pages 1179-1187.e3
Gastroenterology

Original Research
Clinical—Alimentary Tract
Burden of Gastrointestinal Disease in the United States: 2012 Update

https://doi.org/10.1053/j.gastro.2012.08.002Get rights and content

Background & Aims

Gastrointestinal (GI) diseases account for substantial morbidity, mortality, and cost. Statistical analyses of the most recent data are necessary to guide GI research, education, and clinical practice. We estimate the burden of GI disease in the United States.

Methods

We collected information on the epidemiology of GI diseases (including cancers) and symptoms, along with data on resource utilization, quality of life, impairments to work and activity, morbidity, and mortality. These data were obtained from the National Ambulatory Medical Care Survey; National Health and Wellness Survey; Nationwide Inpatient Sample; Surveillance, Epidemiology, and End Results Program; National Vital Statistics System; Thompson Reuters MarketScan; Medicare; Medicaid; and the Clinical Outcomes Research Initiative's National Endoscopic Database. We estimated endoscopic use and costs and examined trends in endoscopic procedure.

Results

Abdominal pain was the most common GI symptom that prompted a clinic visit (15.9 million visits). Gastroesophageal reflux was the most common GI diagnosis (8.9 million visits). Hospitalizations and mortality from Clostridium difficile infection have doubled in the last 10 years. Acute pancreatitis was the most common reason for hospitalization (274,119 discharges). Colorectal cancer accounted for more than half of all GI cancers and was the leading cause of GI-related mortality (52,394 deaths). There were 6.9 million upper, 11.5 million lower, and 228,000 biliary endoscopies performed in 2009. The total cost for outpatient GI endoscopy examinations was $32.4 billion.

Conclusions

GI diseases are a source of substantial morbidity, mortality, and cost in the United States.

Section snippets

Patients and Methods

We compiled the most recently available statistics on GI symptoms, quality of life, outpatient diagnoses, hospitalizations, cost, cancer, mortality, and endoscopic utilization from a variety of publicly and privately held databases. We utilized limited data sets with no direct patient identifiers. Data use agreements were signed as necessary. The methods used to compile the data from the respective source database are detailed below.

Symptoms and Diagnoses

The leading GI symptoms prompting an outpatient clinic visit in 2009 are listed in Table 1. Abdominal pain is the most common GI symptom with an estimated 15.9 million visits in 2009. Other leading symptoms at outpatient visits were diarrhea, constipation, vomiting, and nausea.

The most common physician diagnoses for GI disorders in outpatient clinic visits in 2009 are listed in Table 2. Gastroesophageal reflux was the most frequent outpatient diagnosis with almost 9 million visits in 2009.

Discussion

As detailed above, the toll of GI and liver disease on the US population is extensive. Using the most comprehensive statistical resources available, we present a broad and detailed picture of the current challenges facing these patients and our specialty. Several trends merit special mention.

The toll of C difficile infection is large and becoming more prominent. C difficile hospitalizations have increased by 237% since 2000. This finding is consistent with the documented increase in C difficile

Cited by (0)

This article has an accompanying continuing medical education activity on page e16. Learning Objective: Upon completion of this CME exercise, successful learners will be able to summarize the most recent statistics on key gastrointestinal morbidity, mortality, and cost in adults in the United States.

Conflicts of interest The authors disclose no conflicts.

Funding Supported in part by a grant from the National Institutes of Health (T32 DK07634). Selected data in this manuscript were obtained from the Clinical Outcomes and Research Initiative National Endoscopic Database (CORI-NED), with support from National Institutes of Health (NIDDK) U01-DK57132-01. In addition, CORI has received support from the following entities to support the infrastructure of the practice-based network: AstraZeneca, Novartis, Bard International, Pentax USA, ProVation, Endosoft, GIVEN Imaging, and Ethicon. The commercial entities had no involvement in this research.

View full text